India, June 19 -- French drug major Sanofi (SNY,SAN.PA) announced Friday that Sarclisa (isatuximab) subcutaneous (SC) formulation combination therapy has been approved in Japan for patients with multiple myeloma.
In a statement, the company that the Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa SC formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma.
According to the firm, the approved indications for Sarclisa SC in Japan include in combination with pomalidomide and dexamethasone (Pd), or with carfilzomib for the treatment of relapsed or refractory MM (R/R MM) and in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...